Haemostatic function and biomarkers of endothelial damage before and after platelet transfusion in patients with acute myeloid leukaemia

2015 ◽  
Vol 25 (3) ◽  
pp. 174-183 ◽  
Author(s):  
A. M. Larsen ◽  
E. B. Leinøe ◽  
P. I. Johansson ◽  
R. Larsen ◽  
P. Wantzin ◽  
...  
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Platelet Transfusion ◽  
Endothelial Damage ◽  
Before And After ◽  
Acute Myeloid

scholarly journals Acute myeloid leukaemia presenting with bilateral breast masses

2018 ◽  
pp. bcr-2018-225735
Author(s):  
Kai Chun Andrew Cheng ◽  
Yan-Lin Li ◽  
Tina Lam
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Platelet Transfusion ◽  
Mononuclear Cells ◽  
Breast Masses ◽  
History Of ◽  
Acute Myeloid

A 46-year-old woman with a known history of acute myeloid leukaemia presented with bilateral breast masses with pain and itchiness. The breast masses were hard on palpation. Mammogram was unremarkable. Ultrasound showed multiple conglomerated masses of heterogeneous hyperechogenicity and hypoechogenicity throughout all quadrants of bilateral breasts. Pathology showed mononuclear cells, suggestive of breast leukaemic infiltration. She was treated with decitabine and platelet transfusion.

scholarly journals Non-Neoplastic TdT-Positive Cells in Bone Marrow Trephines with Acute Myeloid Leukaemia before and after Treatment Express Myeloid Molecules

Pathobiology ◽  
2011 ◽  
Vol 78 (1) ◽  
pp. 35-40 ◽  
Author(s):  
Korinna Jöhrens ◽  
Aylin Franke ◽  
Manfred Dietel ◽  
Ioannis Anagnostopoulos
Keyword(s):  
Bone Marrow ◽  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Before And After ◽  
Acute Myeloid

scholarly journals Bone marrow fibre content in acute myeloid leukaemia before and after treatment.

1984 ◽  
Vol 37 (11) ◽  
pp. 1259-1263 ◽  
Author(s):  
A Islam ◽  
D Catovsky ◽  
J M Goldman ◽  
D A Galton
Keyword(s):  
Bone Marrow ◽  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Fibre Content ◽  
Before And After ◽  
Acute Myeloid

scholarly journals Septic shock during platelet transfusion in a patient with acute myeloid leukaemia

2013 ◽  
Vol 2013 (oct30 1) ◽  
pp. bcr2013010412-bcr2013010412 ◽  
Author(s):  
J. Haesebaert ◽  
T. Benet ◽  
M. Michallet ◽  
P. Vanhems
Keyword(s):  
Septic Shock ◽  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Platelet Transfusion ◽  
Acute Myeloid

The acute myeloid leukaemia market

2019 ◽  
Vol 19 (4) ◽  
pp. 233-234
Author(s):  
Jorrit Schaefer ◽  
Sorcha Cassidy ◽  
Rachel M. Webster
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Acute Myeloid

Radioimmunotherapy for treatment of acute myeloid leukaemia and myelodysplastic syndrome

2005 ◽  
Vol 44 (03) ◽  
pp. 107-117
Author(s):  
R. G. Meyer ◽  
W. Herr ◽  
A. Helisch ◽  
P. Bartenstein ◽  
I. Buchmann
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Primary Tumour ◽  
The Other ◽  
Haematopoietic Stem Cell ◽  
Other Hand ◽  
Primary Reduction ◽  
The One ◽  
Acute Myeloid

SummaryThe prognosis of patients with acute myeloid leukaemia (AML) has improved considerably by introduction of aggressive consolidation chemotherapy and haematopoietic stem cell transplantation (SCT). Nevertheless, only 20-30% of patients with AML achieve long-term diseasefree survival after SCT. The most common cause of treatment failure is relapse. Additionally, mortality rates are significantly increased by therapy-related causes such as toxicity of chemotherapy and complications of SCT. Including radioimmunotherapies in the treatment of AML and myelodyplastic syndrome (MDS) allows for the achievement of a pronounced antileukaemic effect for the reduction of relapse rates on the one hand. On the other hand, no increase of acute toxicity and later complications should be induced. These effects are important for the primary reduction of tumour cells as well as for the myeloablative conditioning before SCT.This paper provides a systematic and critical review of the currently used radionuclides and immunoconjugates for the treatment of AML and MDS and summarizes the literature on primary tumour cell reductive radioimmunotherapies on the one hand and conditioning radioimmunotherapies before SCT on the other hand.

Sign in / Sign up

Export Citation Format

Share Document